290 related articles for article (PubMed ID: 22467604)
21. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.
Björklund E; Mazur J; Söderhäll S; Porwit-MacDonald A
Leukemia; 2003 Jan; 17(1):138-48. PubMed ID: 12529671
[TBL] [Abstract][Full Text] [Related]
22. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study.
Borowitz MJ; Pullen DJ; Shuster JJ; Viswanatha D; Montgomery K; Willman CL; Camitta B;
Leukemia; 2003 Aug; 17(8):1566-72. PubMed ID: 12886244
[TBL] [Abstract][Full Text] [Related]
23. [Comparison of the immunophenotype of patients with B lineage acute lymphoblastic leukemia at diagnosis and relapse].
Liu YR; Chang Y; Fu JY; Cheng YF; Zhang LP; Li LD; Wang H; Liu GL; Chen SS; Huang XJ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):335-8. PubMed ID: 16875586
[TBL] [Abstract][Full Text] [Related]
24. Key Markers of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia.
Xia M; Zhang H; Lu Z; Gao Y; Liao X; Li H
J Pediatr Hematol Oncol; 2016 Aug; 38(6):418-22. PubMed ID: 27438018
[TBL] [Abstract][Full Text] [Related]
25. Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection.
Burnusuzov HA; Spasova MI; Murdjeva MA; Stoyanova AA; Mumdziev IN; Kaleva VI; Belcheva MI; Bosheva MN
Folia Med (Plovdiv); 2016 Mar; 58(1):28-35. PubMed ID: 27383875
[TBL] [Abstract][Full Text] [Related]
26. BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation.
Lucio P; Gaipa G; van Lochem EG; van Wering ER; Porwit-MacDonald A; Faria T; Bjorklund E; Biondi A; van den Beemd MW; Baars E; Vidriales B; Parreira A; van Dongen JJ; San Miguel JF; Orfao A;
Leukemia; 2001 Aug; 15(8):1185-92. PubMed ID: 11480560
[TBL] [Abstract][Full Text] [Related]
27. The knowledge on the 3rd type hematogones could contribute to more precise detection of small numbers of precursor B-acute lymphoblastic leukemia.
Babusíková O; Zelezníková T; Mlcáková A; Kusenda J; Stevulová L
Neoplasma; 2005; 52(6):502-9. PubMed ID: 16284697
[TBL] [Abstract][Full Text] [Related]
28. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
[TBL] [Abstract][Full Text] [Related]
29. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study.
Holowiecki J; Krawczyk-Kulis M; Giebel S; Jagoda K; Stella-Holowiecka B; Piatkowska-Jakubas B; Paluszewska M; Seferynska I; Lewandowski K; Kielbinski M; Czyz A; Balana-Nowak A; Król M; Skotnicki AB; Jedrzejczak WW; Warzocha K; Lange A; Hellmann A
Br J Haematol; 2008 Jun; 142(2):227-37. PubMed ID: 18492099
[TBL] [Abstract][Full Text] [Related]
30. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
Zelezníková T; Babusíková O
Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719
[TBL] [Abstract][Full Text] [Related]
31. [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].
Liu YR; Wang YZ; Chen SS; Chang Y; Fu JY; Li LD; Wang H; Yu H; Jiang B; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):731-6. PubMed ID: 18457262
[TBL] [Abstract][Full Text] [Related]
32. Absolute lymphocyte count is associated with minimal residual disease level in childhood B-cell precursor acute lymphoblastic leukemia.
Shen HQ; Feng JH; Tang YM; Song H; Yang SL; Shi SW; Xu WQ
Leuk Res; 2013 Jun; 37(6):671-4. PubMed ID: 23453285
[TBL] [Abstract][Full Text] [Related]
33. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: method and significance.
Dworzak MN; Fritsch G; Panzer-Grümayer ER; Mann G; Gadner H
Leuk Lymphoma; 2000 Jul; 38(3-4):295-308. PubMed ID: 10830736
[TBL] [Abstract][Full Text] [Related]
34. The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: how different are they from their normal counterparts?
Sędek Ł; Bulsa J; Sonsala A; Twardoch M; Wieczorek M; Malinowska I; Derwich K; Niedźwiecki M; Sobol-Milejska G; Kowalczyk JR; Mazur B; Szczepański T
Cytometry B Clin Cytom; 2014 Sep; 86(5):329-39. PubMed ID: 24845957
[TBL] [Abstract][Full Text] [Related]
35. High frequency of heat shock protein 27 overexpression is a highly effective, high-coverage marker for minimal residual disease detection in children with B-cell acute lymphoblastic leukemia.
Chou SW; Su YH; Lu MY; Chang HH; Yang YL; Lin DT; Lin KH; Coustan-Smith E; Jou ST
Pediatr Blood Cancer; 2023 Jan; 70(1):e29990. PubMed ID: 36250996
[TBL] [Abstract][Full Text] [Related]
36. Easy discrimination of hematogones from lymphoblasts in B-cell progenitor acute lymphoblastic leukemia patients using CD81/CD58 expression ratio.
Nagant C; Casula D; Janssens A; Nguyen VTP; Cantinieaux B
Int J Lab Hematol; 2018 Dec; 40(6):734-739. PubMed ID: 30113764
[TBL] [Abstract][Full Text] [Related]
37. [Leukemia-associated immunophenotypes in 415 childhood and adult patients with B lineage acute lymphoblastic leukemia by multiparametric flow cytometry analysis].
Liu YR; Chen SS; Chang Y; Fu JY; Zhang LP; Wang H; Li LD; Zhu HH; Liu GL; Lu DP; Huang XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct; 14(5):853-7. PubMed ID: 17096875
[TBL] [Abstract][Full Text] [Related]
38. Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection.
Gaipa G; Basso G; Maglia O; Leoni V; Faini A; Cazzaniga G; Bugarin C; Veltroni M; Michelotto B; Ratei R; Coliva T; Valsecchi MG; Biondi A; Dworzak MN;
Leukemia; 2005 Jan; 19(1):49-56. PubMed ID: 15538405
[TBL] [Abstract][Full Text] [Related]
39. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR.
Kerst G; Kreyenberg H; Roth C; Well C; Dietz K; Coustan-Smith E; Campana D; Koscielniak E; Niemeyer C; Schlegel PG; Müller I; Niethammer D; Bader P
Br J Haematol; 2005 Mar; 128(6):774-82. PubMed ID: 15755280
[TBL] [Abstract][Full Text] [Related]
40. [Comparative analysis of blast immunophenotype between the diagnosis and relapse of childhood acute lymphoblastic leukaemia - implications for monitoring of minimal residual disease].
Bulsa J; Sedek Ł; Sońta-Jakimczyk D; Mazur B; Sobol G; Szczepański T
Med Wieku Rozwoj; 2008; 12(4 Pt 2):1045-50. PubMed ID: 19531824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
